Allarity Therapeutics (NASDAQ:ALLR) Posts Earnings Results, Beats Expectations By $0.04 EPS

Allarity Therapeutics (NASDAQ:ALLR) announced its quarterly earnings results on Friday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04, FiscalAI reports.

Allarity Therapeutics Price Performance

ALLR stock traded up $0.01 during midday trading on Friday, reaching $1.37. The company had a trading volume of 45,373 shares, compared to its average volume of 163,868. Allarity Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.35. The stock has a 50 day moving average price of $1.31 and a 200-day moving average price of $1.26. The company has a market capitalization of $21.80 million, a price-to-earnings ratio of -1.90 and a beta of 0.51.

Analysts Set New Price Targets

ALLR has been the topic of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets upped their price objective on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research note on Monday, June 8th. Finally, Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Allarity Therapeutics currently has an average rating of “Hold” and an average target price of $10.25.

Hedge Funds Weigh In On Allarity Therapeutics

A number of institutional investors have recently modified their holdings of ALLR. Geode Capital Management LLC grew its holdings in shares of Allarity Therapeutics by 49.3% during the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after purchasing an additional 16,729 shares during the last quarter. Jane Street Group LLC acquired a new position in Allarity Therapeutics in the 2nd quarter worth about $27,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics during the fourth quarter valued at about $36,000. Citadel Advisors LLC acquired a new position in shares of Allarity Therapeutics in the third quarter valued at approximately $149,000. Finally, DRW Securities LLC acquired a new position in shares of Allarity Therapeutics in the fourth quarter valued at approximately $133,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.